Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The principal protein component of paired helical filaments (PHFs) in Alzheimer disease is abnormally hyperphosphorylated tau (PHF-tau). The stress activated protein kinases JNK and p38 have been shown to phosphorylate tau at some sites only seen in PHF-tau. If JNK and p38 are involved in the abnormal hyperphosphorylation of tau, they should be activated in neurons undergoing neurofibrillary degeneration. In the present study, we determined the intracellular and regional distribution of the active forms of JNK and p38 kinase in entorhinal, hippocampal, and temporal cortices of brains staged for neurofibrillary changes according to Braak and Braak. Neurons with tangle-like inclusions positive for active forms of JNK and p38 kinase were found to appear first in the Pre-alpha layer of the entorhinal cortex, and then extend into other brain regions co-incident with the progressive sequence of neurofibrillary changes. The intraneuronal accumulation of active forms of JNK and p38 kinase apeared to precede the deposition of amyloid in the extracellular space. These data indicate that increased activation of the stress related kinases JNK and p38 occurs very early in the disease and might be involved in the intraneuronal protein phosphorylation/dephosphorylation imbalance that leads to neurofibrillary degeneration in Alzheimer disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased p38MAPK activity has been reported in AD brains and lymphocytes [205,206,207,208], as well as in the cortex of a mouse model of AD [209].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [208]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Self-citationBoulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radzlejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., & Yancopoulos, G. D. (1991) · Cell · doi:10.1016/0092-8674(91)90098-j · Cited by 1,897 · cited 1×
“These serine/threonine protein kinases are activated in response to a variety of extracellular stimuli and mediate signal transduction from the cell surface to the nucleus [ 4 ,10].”
BackgroundMicrotubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,778 · cited 1×
“…Bengt Winblada and Richard F. Cowburna aSection for Geriatric Medicine, NEUROTEC, Karolinska Institutet, Novum, KFC, S-141 86 Huddinge, Sweden bDepartment of Anatomy, J.W. Goethe University, Frankfurt, Germany cNYS Institute for Basic Research in Developmental Disabilities, Staten Island, NY,…”
BackgroundSelf-citationConversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., & Tsai, L.-H. (1999) · Nature · doi:10.1038/45159 · Cited by 1,545 · cited 1×
“The intraneuronal accumulation of active forms of JNK and p38 kinase apeared to precede the deposition of amyloid in the extracellular space.”
BackgroundBancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818
Self-citationBraak, F., Braak, H., & Mandelkow, E. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00293315 · Cited by 772
Self-citationPhosphoprotein Phosphatase Activities in Alzheimer Disease Brain
Gong, C., Singh, T. J., Grundke‐Iqbal, I., & Iqbal, K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03603.x · Cited by 527 · cited 1×
“Keywords: Alzheimer’s disease, JNK, p38 kinase, neurofibrillary tangles”
Self-citationPei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459 · cited 2×
“If JNK and p38 are involved in the abnormal hyperphosphorylation of tau, they should be activated in neurons undergoing neurofibrillary degeneration.”
BackgroundSelf-citationVincent, I., Jicha, G., Rosado, M., & Dickson, D. W. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-10-03588.1997 · Cited by 444 · cited 2×
“This type of immunostaining which has also been found to be preferentially associated with active but not with inactive GSK-3 [26], active MAP kinase [27,28], cdc2 [34], cdk5 [24,36] and PKA [19] is reminiscent of classical NFTs, as visualized by silver impregnation, or by immunocytochemistry with mAbs Tau-1 or AT8 [2…”
Background
Cited by
Items 101–168 of 168
A role for mixed lineage kinases in granule cell apoptosis induced by cytoskeletal disruption
Müller, G. J., Geist, M. A., Veng, L., Willesen, M. G., Johansen, F. F., Leist, M., & Vaudano, E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03590.x · Cited by 37
MicroRNAs and MAPKs: Evidence of These Molecular Interactions in Alzheimer’s Disease
Raffaele, I., Silvestro, S., & Mazzon, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054736 · Cited by 35
A Novel Perspective on Tau in Alzheimers Disease
Bonda, D., Castellani, R. J., Zhu, X., Nunomura, A., Lee, H., Perry, G. L., & Smith, M. A. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717131 · Cited by 34
Webber, K. M., Smith, M. A., Lee, H., Harris, P. L. R., Moreira, P. I., Perry, G. L., & Zhu, X. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20380 · Cited by 34
“…et al., 1999; Castellani et al., 2001) and increased activation of signaling pathways involved in cellular response to oxidative stress, namely p38 activation (Hensley et al., 1999; Zhu et al., 2000, 2001b; Ferrer et al., 2001b; Pei et al., 2001; Sun et al., 2003), have been well documented in AD.”
BackgroundLiu, S., Chen, L., Li, J., Sun, Y., Xu, Y., Li, Z., Zhu, Z., & Li, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511976 · Cited by 31
Puig, B., Vinals, F., & Ferrer, I. (2004) · Acta Neuropathologica · doi:10.1007/s00401-003-0793-z · Cited by 27
Agholme, L., Nath, S., Domert, J., Marcusson, J. O., Kågedal, K., & Hallbeck, M. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.11.001 · Cited by 28
“As both ERK 1/2 and the JNK/c-Jun pathway have been implicated inAD (Pei et al., 2001, 2002), wewent on to confirm the activation of c-Jun (Fig.”
Morris, S. L., Tsai, M.-Y., Aloe, S., Bechberger, K., König, S., Morfini, G. A., & Brady, S. T. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.610037 · Cited by 29
“Interestingly, JNKs are well known to be activated in AD (Pei et al., 2001; Zhu et al., 2001; Yarza et al., 2015) and were previously implicated as a downstream effector of trafficking defects in tau knockout Drosophila (Voelzmann et al., 2016).”
BackgroundJin, R., Ning, X., Liu, X., Zhao, Y., & Ye, G. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1141339 · Cited by 32
“Indeed, the activation of P38 MAPK has been verified in the brain during the MCI, both clinically and in mouse models (Pei et al., 2001; Kheiri et al., 2018).”
BackgroundKelliny, S., Lin, L., Deng, I. B., Xiong, J., Zhou, F. H., Al‐Hawwas, M., Bobrovskaya, L., & Zhou, X. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02338-5 · Cited by 24
Focusing on cyclin-dependent kinases 5: A potential target for neurological disorders
Tian, Z., Feng, B., Wang, X.-Q., & Tian, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1030639 · Cited by 25
“Enhanced JNK activity and increased p38 expression were observed in the affected brain areas of AD patients (Pei et al., 2001).”
BackgroundArora, K., Cheng, J., & Nichols, R. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.634162 · Cited by 24
“Studies conducted on post-mortem tissues have confirmed that the activation of MAPK occurs at a very early stage in AD (3, 4).”
BackgroundEmerging role of the Jun N‐terminal kinase interactome in human health
Guo, X., An, S., Yang, Y., Liu, Y., Hao, Q., Tang, T., & Xu, T. (2018) · Cell Biology International · doi:10.1002/cbin.10948 · Cited by 19
“JIP1b couples APP to the JNK pathway, therefore JNK is abnormally activated in the brains of AD patients (Pei et al., 2001; Zhu et al., 2001; Shoji et al., 2000; Yoon et al., 2012).”
BackgroundChaves, R. S., Kazi, A. I., Silva, C. M., Almeida, M. F., Lima, R. S., Carrettiero, D. C., Demasi, M., & Ferrari, M. (2016) · IBRO Reports · doi:10.1016/j.ibror.2016.09.001 · Cited by 22
“…that low concentrations (0.5e1 nM) of rotenone, a mitochondrial complex I inhibitor widely employed in studies related to neurodegeneration (Radad et al., 2008; Ullrich and Humpel, 2009), were able to induce hyperphosphorylation and aggregation of constitutive Tau in the absence of cell…”
BackgroundRecent Understanding of the Molecular Mechanisms of Alzheimer?s Disease
Grimm, M. O. W., & Hartmann, T. (2011) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s5-004 · Cited by 25
Andrés‐Benito, P., Carmona, M., Pirla, M. J., Torrejón-Escribano, B., del Río, J. A., & Ferrer, I. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.10.023 · Cited by 19
Joerchel, S., Raap, M., Bigl, M., Eschrich, K., & Schliebs, R. (2008) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2008.01.004 · Cited by 22
“…p38 and MAPK kinase 6 were found up-regulated in brains from AD patients in a region-specific manner and close association with neurofibrillary tangles and senile plaques, indicating an active role of this pathway in AD pathogenesis (Hensley et al., 1999; Pei et al., 2001; Zhu et al., 2000, 2001).”
BackgroundRole of Metals in Neuronal Apoptosis: Challenges Associated with Neurodegeneration
Ravid, R., & Rao, K. S. J. (2006) · Current Alzheimer Research · doi:10.2174/156720506778249399 · Cited by 19
“Given that MAPK pathways are tightly regulated, the persistent activation of JNK–SAPK and ERK throughout the disease process further indicates that these same “two-hits” are necessary for further disease progression [97, 98].”
BackgroundBridging pathway dysfunction and therapy: novel compounds for neuroprotection
Patel, S., Prajapati, C., Nand, S., & Singh, S. K. (2026) · 3 Biotech · doi:10.1007/s13205-026-04697-z · Cited by 20
Kim, M., Ryu, J., & Hah, J.-M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.082 · Cited by 16
The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo
Salomon‐Zimri, S., Koren-Iton, A., Angel, A., Ben‐Zur, T., Offen, D., & Michaelson, D. M. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190228120254 · Cited by 18
Iqbal, S., Raju, P., S, N. S., Lokanath, N. K., Mohanakrishnan, A. K., & Gunasekaran, K. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1877197 · Cited by 15
“Activation of p38 alpha occurs through bis-phosphorylation on the Thr 180-Gly181-Tyr182 motif located in the activation loop by dual specificity Ser/Thr MAP kinases, MKK3 and MKK6 (Ferrer et al., 2005; Hensley et al., 1999; Pei et al., 2001; Zhu et al., 2001).”
BackgroundSahara, N., Vega, I. E., Ishizawa, T., Lewis, J., McGowan, E., Hutton, M., Dickson, D., & Yen, S. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02558.x · Cited by 15
Acetaldehyde induces tau phosphorylation via activation of p38 MAPK/JNK and ROS production
Li, T., Shi, H., & Zhao, Y. (2021) · Molecular & Cellular Toxicology · doi:10.1007/s13273-021-00193-y · Cited by 13
Koss, D. J., & Platt, B. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000299 · Cited by 13
“Postmortem studies further support this association, with progression of tau pathology in human AD, that is, high cytoplasmic levels are found in neurofibrillary tanglebearing neurons but also in a considerable number of taupositive neurons without mature aggregates (Pei et al., 2001; Lagalwar et al., 2006).”
BackgroundChlan‐Fourney, J., Zhao, T., Walz, W., & Mousseau, D. D. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07597.x · Cited by 11
“…(Koistinaho et al., 2002; Puig et al., 2004) and, although celldependent p38(MAPK) signalling could be detrimental in AD (Hensley et al., 1999; Pei et al., 2001; Savage et al., 2002; Bellucci et al., 2007), the recruitment of microglia [many of which are p-p38(MAPK)-IR (Giovannini et al.,…”
BackgroundGene-environment interplay in neurogenesis and neurodegeneration
Palomo, T., Archer, T., Beninger, R. J., & Kostrzewa, R. M. (2004) · Neurotoxicity Research · doi:10.1007/bf03033279 · Cited by 14
“…p38 and PKA in tau deposits and NFTs (Hensley et al., 1999; Knowles et al., 1999; Perry et al., 1999; Zhu et al., 2000; 2001; 2002; Atzori et al., 2001; Ferrer et al., 2001a,b; Pei et al., 2001) and in AD, PSP, CBD and PiD (Atzori et al., 2001; Ferrer et al., 2001a,b; Hartzler et al., 2002).”
BackgroundBAG2 prevents Tau hyperphosphorylation and increases p62/SQSTM1 in cell models of neurodegeneration
Lima, R. S., Carrettiero, D. C., & Ferrari, M. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07577-w · Cited by 11
“Several kinases can trigger Tau phosphorylation, such as glycogen synthase kinase-3b (GSK3b), c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase (MAPK), all associated with AD progression [36].”
BackgroundIdentification and characterization of bi-thiazole-2,2′-diamines as kinase inhibitory scaffolds
Ngoei, K. R. W., Ng, D. C. H., Gooley, P. R., Fairlie, D. P., Stoermer, M. J., & Bogoyevitch, M. A. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.02.001 · Cited by 10
“Recent reports have implicated actions of JNKs in various diseases such as stroke [13,14], neurodegenerative disorders including Alzheimer's disease [15,16] and Parkinson's disease [17], type-2 diabetes [18,19], inflammation [20–22] and cancer [23,24].”
BackgroundA Mutant Variant of E2F4 Triggers Multifactorial Therapeutic Effects in 5xFAD Mice
López‐Sánchez, N., Ramón‐Landreau, M., Trujillo, C., Garrido‐García, A., & Frade, J. M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02764-z · Cited by 8
DNA-PK and P38 MAPK: A Kinase Collusion in Alzheimer’s Disease?
Kanungo, J. (2017) · Brain Disorders & Therapy · doi:10.4172/2168-975x.1000232 · Cited by 8
“Activation of p38 MAPK by DSB-inducing agents occurs via phosphorylation of p38 MAPK itself [94].”
BackgroundKinase inhibition in Alzheimer’s disease
Bagheri, S., & Saboury, A. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00003-x · Cited by 7
Pereira, J. D., Teixeira, L. C. R., Mamede, I., Alves, M. T., Caramelli, P., Luizon, M. R., Veloso, A., & Gomes, K. B. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16060 · Cited by 6
“Moreover, this increase was reported to occur in the early stages of AD, and it has also been found that MAPK kinase 6 (MKK6), an up-stream activator of p38 MAPK, is up-regulated in brains of diseased individuals (Pei et al., 2001 ; Zhu et al., 2001 ).”
BackgroundApoptosis vs Nonapoptotic Mechanisms in Neurodegeneration
Jellinger, K. A. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-297-5_2 · Cited by 8
Biomarker identification for diagnosis of Alzheimer's disease
Pelech, S. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2.5.577 · Cited by 6
Molecular Modeling of Tau Proline-Directed Protein Kinase (PDPK) Inhibitors
Navarro‐Retamal, C., & Caballero, J. (2017) · Neuromethods · doi:10.1007/978-1-4939-7404-7_13 · Cited by 7
JNK-interacting protein 1 mediates Alzheimer's-like pathological features in AICD-transgenic mice
Margevicius, D., Bastian, C., Fan, Q., Davis, R. J., & Pimplikar, S. W. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.013 · Cited by 8
“Aberrantly-activated JNK is observed in human AD brains (Pei et al., 2001; Yoon et al., 2012; Zhu et al., 2001) and activated JNK has been shown to phosphorylate tau (Orejana et al., 2013; Reynolds et al., 1997), to stimulate the release of proinflammatory cytokines (Arthur and Ley, 2013), to…”
BackgroundInfluentialChen, T., Chen, Y., Hsu, M.-L., Liao, Y. J., Wu, C.-H., Yao, C., Yang, W., Lin, W., & Lin, Y. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c07659 · Cited by 5
From Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer’s Disease Landscape
Bougea, A. M., Debasa‐Mouce, M., Gulkarov, S., Castro‐Mosquera, M., Reiss, A. B., & Ouro, A. (2025) · Medicina · doi:10.3390/medicina61081462 · Cited by 8
“In addition, Pei et al. showed that p38 MAPK activity is elevated in the cortex and hippocampus of both AD mice and patients, at relatively early stages of disease progression [141].”
Ramón‐Landreau, M., Sánchez‐Puelles, C., López‐Sánchez, N., Lozano-Ureña, A., Llabrés-Mas, A. M., & Frade, J. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012093 · Cited by 8
Understanding the Structure and Apo Dynamics of the Functionally Active JIP1 Fragment
Ojaghlou, N., Airas, J., McRae, L. M., Taylor, C., Miller, B. R., & Parish, C. A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01008 · Cited by 4
Role of tau in Alzheimer's dementia and other neurodegenerative diseases
Quadros, A., Weeks, O. I., & Ait‐Ghezala, G. (2007) · Journal of Applied Biomedicine · doi:10.32725/jab.2007.001 · Cited by 5
“…indicate that increased activation of the stress related kinases JNK and p38 occurs very early in the disease and might be involved in the intraneuronal protein phosphorylation/ dephosphorylation imbalance that leads to neurofibrillary degeneration in AD (Reynolds et al. 2000, Pei et al. 2001).”
BackgroundAmyloid‐Like Fibrils: Origin, Structure, Properties, and Potential Technological Applications
Taboada, P., Barbosa, S., Juárez, J., Alatorre‐Meda, M., & Mosquera, V. (2013) · Wiley eBooks · doi:10.1002/9781118523063.ch12 · Cited by 6
Hu, M., Li, A. Z., Fleming, P., Gralla, J., Terón, K. I. N., Zhou, Y., Miller, E. J., Beyett, T. S., Wen, Z., Du, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01425 · Cited by 3
Effects of Epigallocatechin-3-O-Gallate on Bone Health
Wróbel, P., Czarczyńska-Goślińska, B., Chornovolenko, K., Liwarska, J., Kubiak, J., Koczorowski, T., Malińska, A., Gośliński, T. A., & Waszyk-Nowaczyk, M. (2025) · Applied Sciences · doi:10.3390/app15158182 · Cited by 3
Immediate Early Genes, Inducible Transcription Factors and Stress Kinases in Alzheimer’s Disease
Ferrer, I., Santpere, G., & Puig, B. (2006) · Springer eBooks · doi:10.1007/978-0-387-33604-6_13 · Cited by 3
Targeting of kinases to treat neurodegenerative diseases
Shomali, T., & Trempe, J.-F. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100128 · Cited by 5
“11 In PD, elevated JNK activity has also been observed in human substantia nigra tissue, consistent with findings from dopaminergic neurotoxin models such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-OHDA.”
Neuroprotective Effects of Extra‐Virgin Olive Oil and its Components in Alzheimer's Disease
Abuznait, A. H., Qosa, H., Mohamed, L. A., Batarseh, Y. S., & Kaddoumi, A. (2017) · Wiley eBooks · doi:10.1002/9781119155195.ch14 · Cited by 2
Cyclopropyl as a versatile tool in the development of kinase-targeted therapeutics
Liu, W., Huang, Y., Hao, W., Rong, Z., Liu, X., Zhou, Y., Song, S., & Pang, X. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118761 · Cited by 2
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1
“Consistently, Pei et al. demonstrated elevated p38 MAPK activity in the cortex and hippocampus of both AD patients and mouse models, even at early stages of the disease (Pei et al., 2001).”
Li, Y., Xu, X., Meng, Z., Chen, L., Yu, Q., Wang, R. K., Ren, Y., Chen, F., Liang, G., Zhao, X. P., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116887 · Cited by 2
“…of NDs. 48–51 Studies have shown that p38 MAPK activity is significantly elevated in the hippocampus and cortex during early AD stages and is present in both neurons and glial cells, 52–54 suggesting that inhibition of p38 MAPK signaling may represent a potential therapeutic strategy for AD.”
Tau Pathology as a Target in Alzheimer's Therapeutics
Iqbal, K., & Grundke, I. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_14 · Cited by 1
Self-citationNeuroprotective strategies in Alzheimer’s disease
Longo, F. M., & Massa, S. M. (2004) · Neurotherapeutics · doi:10.1007/bf03206572 · Cited by 7
Control of cell cycle progression at S phase by the yeast MAPK Hog1
Yaakov, G. (2008) · Cited by 1
E2F4 as a single multifactorial target against Alzheimer’s diseasePreprint
López‐Sánchez, N., Ramón‐Landreau, M., Trujillo, C., Garrido‐García, A., & Frade, J. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.08.082784 · Cited by 1
Metabolic Abnormalities in Alzheimer Disease
Gebhardt, F. M., & Dodd, P. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-79112-8_22 · Cited by 2
Cooperative calcium and zinc signaling underlies oxidantinduced neuronal injury
McCord, M. C. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
In vitro modelling of tau phosphorylating kinases : emphasis of Cdk5
Jämsä, A. (2007) · Figshare · Cited by 2
Role of P70 S6 kinase in the formation of tau pathologies in Alzheimer´s disease
An, W. (2005) · Figshare · Cited by 1
Liao, Y.-F., Kuo, L.-H., & Tung, Y. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.081
Cunningham, J. G. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7739
Wu, Z., Jin, H., Shuai, B., Zhang, X., Wang, S., Chen, L., & Huang, B. (2025) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2025.j102
Oxidative Stress Associated Signal Transduction Cascades in Alzheimer Disease
Petersen, R. B., Nunomura, A., Lee, H., Casadesús, G., Perry, G. L., Smith, M. A., & Zhu, X. (2009) · Contemporary clinical neuroscience · doi:10.1007/978-1-60327-342-8_8
Viana, R. J. S. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
BindingDB Entry 50031494: Small molecule JNK (c-Jun N-terminal kinase) inhibitors.
BindingDB (2010) · UC San Diego · doi:10.7270/q2ks6rp5
Metadata
- Authors
- Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F.
- Affiliations
- Karolinska Institutet (SE)
- Goethe University Frankfurt (DE)
- NYS Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2001-03-05
- Volume
- 3
- Issue
- 1
- Pages
- 41-48
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W86871181
- Cited by
- 165
- References
- 26
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 2 · 2015: 7 · 2014: 6 · 2013: 6 · 2012: 7
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Alzheimerfonden
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, c-Jun kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.